Long‐term mortality after status epilepticus: A 5‐year analysis study
Epilepsia · 2026
DOI: 10.1002/epi.70363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2026. Verfasst von Manuel Alanís-Bernal und 10 weiteren Autor:innen. Beteiligte Einrichtung: Epilepsy Unit, Neurology Department. Vall d'Hebron Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Status Epilepticus. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objective
To describe 5‐year mortality after status epilepticus (SE) and identify factors associated with long‐term survival. We also validated the prognostic performance of the Age, Consciousness, Duration (ACD) score and evaluated long‐term survival across etiological categories defined by the Lattanzi classification of acute symptomatic SE.
Methods
Retrospective cohort analysis of a prospectively maintained database of consecutive patients ≥16 years of age with confirmed SE admitted to a tertiary epilepsy center (2011–2022). We excluded unclear diagnoses, hypoxic–anoxic etiologies, and incomplete follow‐up. We recorded clinical variables and prognostic scores modified Status Epilepticus Severity Score (mSTESS), Epidemiology‐based Mortality Status Epilepticus (EMSE), and Age, Consciousness, Duration (ACD). Mortality was assessed at discharge and annually up to 5 years.
Results
We included 786 patients (mean age 63.4 years, 43.5% female). Five‐year mortality was 50.3%, with 44.0% of deaths occurring within the first 2 years. Neurological causes accounted for 60.8% of deaths, and direct seizure‐related causes represented 74.6% of neurological deaths. Independent predictors of higher long‐term mortality were older age, higher premorbid mRS, absence of prior seizure history, comorbidity burden, systemic complications, and impaired consciousness during SE; convulsive and focal motor SE were associated with lower mortality risk. mSTESS and EMSE were associated with long‐term mortality. In patients with less damaging etiologies, ACD predicted 5‐year mortality (hazard ratio [HR] 1.163, 95% confidence interval [CI] 1.063–1.273; area under the curve [AUC] 0.717); ACD ≥10 corresponded to >50% 2‐year mortality. Five‐year mortality was 61.3% (acute‐primary Central Nervous System (CNS) and 58.3% (acute‐secondary CNS). Significance SE carries substantial long‐term mortality, particularly within the first 2 years. Neurological and seizure‐related causes were the most frequent. The Lattanzi classification and the ACD score retained long‐term prognostic value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Epilepsy Unit, Neurology Department. Vall d'Hebron Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Research Group on Status Epilepticus and Acute Seizures, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
- Neurology Department. Vall d'Hebron Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
ORCID-Profile: Manuel Alanís-Bernal, Daniel Campos-Fernández, Laura Abraira, Laura Gómez-Dabó, Marc Rodrigo-Gisbert, Manuel Quintana, Sofía Lallana, Elena Fonseca, Samuel López-Maza, Manuel Toledo, Estevo Santamarina
Zitieren
APA
Alanís-Bernal, M., Campos-Fernández, D., Abraira, L., Gómez-Dabó, L., Rodrigo-Gisbert, M., Quintana, M., Lallana, S., Fonseca, E., López-Maza, S., Toledo, M., & Santamarina, E. (2026). Long‐term mortality after status epilepticus: A 5‐year analysis study. Epilepsia. https://doi.org/10.1002/epi.70363
Vancouver
Alanís-Bernal M, Campos-Fernández D, Abraira L, Gómez-Dabó L, Rodrigo-Gisbert M, Quintana M, et al. Long‐term mortality after status epilepticus: A 5‐year analysis study. Epilepsia. 2026. doi:10.1002/epi.70363
BibTeX
@article{AlansBernal2026,
author = {Alanís-Bernal, Manuel and Campos-Fernández, Daniel and Abraira, Laura and Gómez-Dabó, Laura and Rodrigo-Gisbert, Marc and Quintana, Manuel and Lallana, Sofía and Fonseca, Elena and López-Maza, Samuel and Toledo, Manuel and Santamarina, Estevo},
title = {Long‐term mortality after status epilepticus: A 5‐year analysis study},
journal = {Epilepsia},
year = {2026},
doi = {10.1002/epi.70363}
}
EUVIMED